MKI67 and cancer: Despite the obvious need for improved patient stratification and numerous studies suggesting novel cancer biomarkers, clinical decision making is at large dependent on morphological assessment and IHC staining based on proliferation (Ki-67), hormone receptor status and expression of HER2 [31].